Despite a Q1 Drop in Sales, J&J Anticipates New Indications Will Increase Xarelto Revenue Growth - BioSpace

Despite a Q1 Drop in Sales, J&J Anticipates New Indications Will Increase Xarelto Revenue Growth  BioSpace

Life sciences giant blamed the Medicare "doughnut hole" and increased competition for the blood thinner's declining sales.